Cart
sales@molnova.com
SDMA
CAS No. 30344-00-4
SDMA( NG,NG'-Dimethyl-L-arginine )
Catalog No. M13956 CAS No. 30344-00-4
SDMA (Symmetric dimethylarginine) is an arginine derivative and an endogenous inhibitor of nitric oxide (NO) synthase activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 5MG | 32 | In Stock |
|
| 10MG | 52 | In Stock |
|
| 25MG | 96 | In Stock |
|
| 50MG | 162 | In Stock |
|
| 100MG | 255 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSDMA
-
NoteResearch use only, not for human use.
-
Brief DescriptionSDMA (Symmetric dimethylarginine) is an arginine derivative and an endogenous inhibitor of nitric oxide (NO) synthase activity.
-
DescriptionSDMA (Symmetric dimethylarginine) is an arginine derivative and an endogenous inhibitor of nitric oxide (NO) synthase activity.
-
In Vitro——
-
In Vivo——
-
SynonymsNG,NG'-Dimethyl-L-arginine
-
PathwayImmunology/Inflammation
-
TargetNOS
-
RecptorNOS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number30344-00-4
-
Formula Weight202.25412
-
Molecular FormulaC8H18N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 8.33 mg/mL
-
SMILESCNC(=NC)NCCCC(C(=O)O)N
-
Chemical NameL-Ornithine, N5-[(methylamino)(methylimino)methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. MacAllister RJ, et al. Br J Pharmacol. 1994 May;112(1):43-8.
2. Das I, et al. Neurosci Lett. 1996 Sep 13;215(3):209-11.
3. Tojo A, et al. Kidney Int. 1997 Dec;52(6):1593-601.
4. Leiper J, et al. Cardiovasc Res. 1999 Aug 15;43(3):542-8.
molnova catalog
related products
-
Micheliolide
Micheliolide(MCL) is a sesquiterpene lactone which inhibits various inflammatory response.
-
nNOS-IN-25
A potent, selective cell permeable neuronal nitric oxide synthase (nNOS) inhibitor with Ki of 30 nM.
-
ETHYL CAFFEATE b
In vitro ECF suppressed the differentiation of naive CD4+ T cells into Th1. Furthermore ECF intensely blocked the transcriptional expression in interferon-γ-related signaling including IFN-γ T-bet STAT1 and STAT4.?
